| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $639.7M | +6.9% | +45.6% |
| Cost of Revenue | $356.1M | +4.3% | +43.0% |
| R&D Expense | $24.6M | +280.9% | +503.9% |
| SG&A Expense | $177.9M | +71.6% | +106.6% |
| Operating Income | -$60.2M | -299.7% | -440.9% |
| Income Tax | -$32.2M | -499.5% | -724.2% |
| Net Income | -$59.1M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $312.8M | — | — |
| Accounts Receivable | $106.1M | — | — |
| Inventory | $268.9M | — | — |
| Current Assets | $718.1M | — | — |
| Total Assets | $843.1M | — | — |
| Current Liabilities | $279.0M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $90.9M | — | — |
| Capital Expenditures | $15.2M | — | — |
| Investing Cash Flow | -$15.2M | — | — |
| Financing Cash Flow | $61.6M | — | — |
| Free Cash Flow | $75.7M | — | — |
| -348.3% |
| -516.0% |
| EPS (Basic) | -$2.19 | -1316.7% | -2533.3% |
| EPS (Diluted) | -$2.19 | -1316.7% | -2533.3% |
| — |
| Total Liabilities | $301.7M | — | — |
| Stockholders' Equity | $541.4M | +249.1% | +477.8% |